Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes

Moderna, Inc. (NASDAQ:MRNA) is among the stocks in focus as Jim Cramer reviewed the S&P 500’s top performers and the Nasdaq 100’s biggest laggards for the first quarter. Cramer highlighted the bullish environment around the stock, as he said:

Finally, aside from the data center plays and the commodity plays, there’s a one-off in the top 10 list, and that’s Moderna, up 72% in the first quarter, the sixth best performer in the S&P. Moderna cleaned up during the pandemic, but then spent years lost in the wilderness as they never came up with anything that could replace the COVID vaccine. Lately, though, the stock’s been breaking out, settling key lawsuits that have been an overhang, getting its new flu vaccine reviewed by a previously hostile FDA. And then last month, we learned that Dr. Vinay Prasad, that’s the vaccine skeptic who RFK Jr put in charge of the vaccines at the FDA, he’ll be leaving at the end of this month. Great news for Moderna, which is primarily a vaccine company.

Photo by Ian Hutchinson on Unsplash

Moderna, Inc. (NASDAQ:MRNA) makes mRNA medicines and vaccines to protect against illnesses like the flu, COVID-19, and some other viruses. The company also works on treatments for cancer and rare diseases.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.